Eli Lilly is set to launch an innovative oral medication for obesity treatment. Orforglipron, a GLP-1 agonist, has shown promising results in clinical trials and may offer an effective alternative to the currently available injectable treatments.
📈 Promising Clinical Trial Results
In a Phase 3 study involving over 1,600 adults with type 2 diabetes, patients taking the highest dose of 36 mg of orforglipron lost an average of 10.5% of their body weight—roughly 23 pounds (10.43 kg).
“75% of patients receiving this dose reduced their hemoglobin A1C levels to 6.5% or lower, reaching the target recommended by the American Diabetes Association,” the study reported.
In another study with obese adults without diabetes, the same 36 mg dose resulted in an average weight loss of 12.4% over 72 weeks. These results are competitive with injectable treatments such as Novo Nordisk’s Wegovy.
Production and Regulatory Approval
Eli Lilly plans to submit orforglipron for obesity treatment approval by the end of 2025, with approval for type 2 diabetes expected the following year. The company is investing heavily in manufacturing, including a new $6.5 billion plant in Texas.
Market Potential
Analysts estimate that orforglipron could generate up to $25 billion in annual sales at peak market. The pill is expected to launch globally in 2026, providing a more convenient and accessible option for patients who currently rely on weekly injections.
Expert Statements
Kenneth Custer, president of Eli Lilly’s cardiometabolic health division, stated:
“Orforglipron is a promising alternative to injectables, with the potential to be manufactured at scale.”
Citi Research analysts also highlighted the drug as an attractive option for patients, noting that “the FDA program is a perfect match for Lilly’s pill.”
Source: Reuters, September 16, 2025 – “Eli Lilly’s New Oral Weight Loss Pill Could Revolutionize Obesity Treatment”
